Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction

Overview

The purpose of this study is to demonstrate the efficacy of 0.2 % digluconate chlorhexidine mouthwash in the prevention of alveolar osteitis following third molar extraction and to evaluate the safety and local tolerability.

Full Title of Study: “Efficacy of DC071 Mouthwash (0.2% Chlorhexidine Digluconate) in Peri-surgical Care for Preventing Alveolar Osteitis After Third Molar Extraction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 2016

Interventions

  • Drug: DC071
    • Mouthwash, twice daily
  • Drug: Placebo
    • Mouthwash, twice daily

Arms, Groups and Cohorts

  • Experimental: DC071 (0.2% chlorhexidine digluconate)
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Occurrence of an alveolar osteitis
    • Time Frame: Within 7 days
    • The primary Outcome measure will be evaluated based on the absence/presence of an alveolar osteitis within 7 days after the extraction of the third molar.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female over 18 years old – Subject needing to undergo extraction of one impacted mandibular third molar – For woman of childbearing potential and woman in post menopausal period under hormonal substitution treatment, she must accept to plan the extraction of the impacted mandibular third molar only during the last week of the menstrual cycle. – Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation) Exclusion Criteria:

  • Existence or history of parotid gland disorders – Acute or history of recent acute pericoronitis at any tooth – Extraction of more than 1 third molar in the same surgical procedure – Subject at high risk of bacterial endocarditis (prosthetic heart valve, history of bacterial endocarditis, congenital cyanogenic heart disease) – Coagulation or haemostatic disorder or use of anticoagulants – Hypersensitivity to chlorhexidine or any of the excipients; – Hypersensitivity to any anesthetic agent; – Hypersensitivity to corticosteroids, analgesics including opioid drugs used for post-surgery pain relief – Intake of systemic vasodilator or vasoconstrictor – Intake of systemic or local (in the mouth) antibiotics within 7 days before Day 1 and/or any pre- or post-operative antibiotic prophylaxis planned to be prescribed during the study; – Use of any antiseptic mouthwash within 7 days before Day -1 – Regular heavy smokers (more than 20 cigarettes per day) – Is pregnant or in post-partum period or a nursing mother

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pierre Fabre Medicament
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Françoise TONNER, Study Director, Pierre Fabre Medicament

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.